Development of a Nomogram Model for Predicting the Risk of In-Hospital Death in Patients with Acute Kidney Injury

Xiuying Yao¹,*
Lixiang Zhang²,*
Lei Huang¹,*
Xia Chen²,*
Li Geng¹
Xu Xu¹

¹Department of Intensive Care Unit, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230036, People’s Republic of China; ²Department of Nursing Department, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230036, People’s Republic of China

*These authors contributed equally to this work

Objective: To analyze the risk factors of in-hospital death in patients with acute kidney injury (AKI) in the intensive care unit (ICU), and to develop a personalized risk prediction model.

Methods: The clinical data of 137 AKI patients hospitalized in the ICU of Anhui provincial hospital from January 2018 to December 2020 were retrospectively analyzed. Patients were divided into two groups: those that survived to discharge ("survival" group, 100 cases) and those that died while in hospital ("death" group, 37 cases), and risk factors for in-hospital death analyzed.

Results: The in-hospital mortality of AKI patients in the ICU was 27.01% (37/137). A multivariate logistic regression analysis indicated age, mechanical ventilation and vasopressor drugs were significant risk factors for in-hospital death in AKI patients, and a nomogram risk prediction model was developed. The Harrell’s C-index of the nomogram model was 0.891 (95% CI: 0.837–0.945), and the area under the receiver operating characteristic (ROC) curve was 0.886 (95% CI: 0.823–0.936) after internal validation, indicating that the nomogram model had good discrimination. The Hosmer–Lemeshow goodness of fit test and calibration curve indicated the predicted probability of the nomogram model was consistent with the actual frequency of death in ICU patients with AKI. The decision curve analysis (DCA) showed that the clinical net benefit level of the nomogram model is highest when the probability threshold of AKI is between 0.01 and 0.75.

Conclusion: Patients in the ICU with AKI had high in-hospital mortality and were affected by a variety of risk factors. The nomogram prediction model based on the risk factors of AKI showed good prediction efficiency and clinical applicability, which could help medical staff in the ICU to identify AKI patients with high-risk, allowing early prevention, detection and intervention, and reducing the risk of in-hospital deaths in ICU patients with AKI.

Keywords: AKI, ICU, inpatient mortality, risk factors, prediction risk model

Introduction

Acute kidney injury (AKI) is one of the most common critical diseases in hospitalized patients and has a high incidence rate and mortality.ⁱ Studies² reveal that more than 15% of hospitalized patients and 60% of critically ill patients may develop AKI. With age, as body functions gradually decline, and when combined with multiple organ diseases, the incidence rate of AKI gradually increases. The complication of AKI in inpatients often leads to a prolonged hospital stay, creating an increased burden of hospitalization expenses, increased hospital mortality, permanent damage in renal function, etc. The mortality rate of AKI inpatients can be as high as 15.8–22.4%.³,⁴
A multicenter survey in China showed that the median length of stay for AKI inpatients in general hospitals in China is 18 days, and the in-hospital mortality rate is 12.4%. FENG et al, in a Chinese multicenter prospective epidemiological study of AKI, found that in-hospital mortality rate of AKI inpatients was 9.24%, that nephrology and ICU were high risk departments for AKI, especially critically ill patients in the ICU, and that AKI was an independent risk factor for increased mortality.

AKI not only increases the mortality of patients, but also may lead to the occurrence of chronic kidney disease (CKD), end-stage renal disease (ESRD) and adverse cardiovascular events. Therefore, it is clinically important to identify the relevant risk factors of a short-term adverse prognosis from AKI and take targeted intervention strategies to reduce the risk of such events. This study retrospectively analyzed the clinical data of 137 AKI patients hospitalized in the ICU of Anhui provincial hospital from January 2018 to December 2020 and developed the first nomogram prediction model to predict the risk of in-hospital death from AKI in China. The goal is to screen AKI patients for those with a high risk of death so that targeted prevention and intervention strategies can be taken to reduce the incidence of in-hospital death in AKI patients.

Materials and Methods

Research Subjects

Research subjects were 137 AKI patients hospitalized in the ICU of Anhui provincial hospital from January 2018 to December 2020. The inclusion criteria were as follows. 1) All research subjects met the AKI diagnostic criteria recommended by KDIGO guidelines, ie, they met one of the following three conditions: an increased serum creatinine (SCr) level ≥26.5 μmol/l within 48 h; a SCr level within 7 days that was 1.5 times the baseline level; or, a urine volume <0.5 mL/kg/h for more than 6 h. 2) Clinical data were complete. 3) Length of hospital stay was >24 h. Exclusion criteria were: 1) baseline SCr level <40 μmol/L; and 2) patients with a kidney transplant or on maintenance hemodialysis. The study protocol was approved by the medical ethics committee of The First Affiliated Hospital of the University of Science and Technology of China (2021-RE-037) and followed the guidelines of the “Declaration of Helsinki.” As this was a retrospective study and the data were analyzed anonymously, informed consent of the subjects was not required.

Data Collection

The clinical data of the 137 patients were collected and analyzed retrospectively, including demographic data, disease-related data, laboratory examination results within 24 hours after AKI, drug and surgical treatment, and complications. Variables recorded included gender; age; blood pressure and mean arterial pressure within 24 hours after AKI; the use of cardio-pulmonary resuscitation (CPR), mechanical ventilation (MV) or surgical treatment during hospitalization; whether the complications of shock (including hemorrhagic shock, septic shock, cardiogenic shock), sepsis or organ failure (including liver failure, heart failure, respiratory failure) occurred, use of vasoactive drugs, hemodialysis, or continuous renal replacement therapy (CRRT). Specific analysis indicators are detailed in Table 1. The 137 patients were divided into “survival” (100 cases) and “death” (37 cases) groups based on whether they survived to discharge or not, respectively.

Statistical Methods

All data were analyzed using R software (R 3.6.1). Continuous data that met assumptions of a normal distribution were summarized using mean ± standard deviation (SD), and an independent sample t-test was used for comparison between groups. The median plus quartiles 1 and 3 (Q1, Q3) were used to summarize continuous data that did not conform to the normal distribution, and the Mann–Whitney test was used to compare between groups. Classification data were expressed as the number of cases, percentage or rate. The Pearson chi-square test or Fisher’s exact probability method were used for comparison between groups in category data. The least absolute shrinkage and selection operator (LASSO) regression method was used to identify the relevant variables for in-hospital death in AKI patients, and then a stepwise multivariate logistic regression analysis based on the minimum Akaike information criterion (AIC) was used to identify the independent risk factors of in-hospital death in AKI patients. The nomogram model and calibration curve were plotted using the “rms” package (Regression Modeling Strategies) in R software. The receiver operating characteristic (ROC) curve of the nomogram model was plotted using the “pROC” package (an open-source package for R and S+), and an independent sample t-test to analyze and compare ROC curves). The “rmda” package (Risk Model Decision Analysis) was used to plot the decision curve analysis (DCA) curve of the nomogram model. To prevent overfitting of the nomogram model, and following the prediction model establishment and internal validation.
Table 1 Univariate Analysis of the Risk of Poor Prognosis in ICU Inpatients with AKI

| Variables                                      | Total (n = 137) | Survival Group (n = 100) | Death Group (n = 37) | Statistic | P     |
|------------------------------------------------|----------------|--------------------------|---------------------|-----------|-------|
| Age                                            | 64 (52, 74)    | 61.5 (49.75, 70)        | 73 (63, 77)         | −3.46\(^a\) | <0.001|
| Systolic blood pressure within 24 hours after Aki| 109 (97, 140) | 123.5 (99.75, 146.5)    | 100 (90, 106)       | 4.228\(^a\) | <0.001|
| Diastolic blood pressure within 24 hours after Aki | 67 (52, 80)    | 72 (57.75, 84.25)       | 55 (45, 64)         | 3.618\(^a\) | <0.001|
| Mean arterial pressure within 24 hours after Aki | 83 (66.33, 100) | 89 (71.92, 102.42)      | 67 (64, 76.33)      | 4.06\(^a\)  | <0.001|
| SCr                                            | 336.95 (188, 518.3) | 349 (186.5, 542)      | 302 (190.5, 480)   | 0.868\(^a\) | 0.386 |
| Blood urea nitrogen                             | 28.56 (15.64, 37.3) | 28.63 (15.5, 36.48)    | 28.54 (20.8, 39.1) | −0.722\(^a\) | 0.470 |
| Uric acid                                       | 533 (404, 672)  | 534.5 (411, 666.45)     | 522 (371, 675)     | 0.264\(^a\) | 0.792 |
| Cystatin C                                      | 2.72 (1.75, 4)  | 2.71 (1.7, 4.23)        | 2.81 (1.85, 3.37)  | 0.432\(^a\) | 0.666 |
| Albumin value                                   | 31.5±6±32      | 32.53±5.99              | 28.84±6.49         | 3.137\(^b\) | 0.002 |
| Platelet value                                  | 137 (96, 183)  | 146.5 (107.5, 191.25)   | 108 (76, 145)      | 2.943\(^a\) | 0.003 |
| Hemoglobin value                                | 94 (80, 114)   | 94 (80.75, 111.5)       | 91 (77, 123)       | −0.056\(^a\) | 0.956 |
| Erythrocrit                                      | 0.28 (0.24, 0.33) | 0.28 (0.24, 0.34)     | 0.27 (0.22, 0.33)  | 0.55\(^a\)  | 0.582 |
| White blood cell count (× 10\(^3\))            | 9.17 (6.27, 14.67) | 8.15 (5.72, 13.88)    | 12.7 (8.93, 16.45) | −2.412\(^a\) | 0.016 |
| Percentage of neutrophils (%)                   | 59.2 (13.12, 84) | 61.45 (12.57, 80.78)   | 51.9 (13.53, 88.9) | −0.64\(^a\)  | 0.522 |
| Lymphocyte percentage (%)                       | 4.3 (0.76, 15)  | 5.88 (0.84, 16.95)      | 2.4 (0.67, 6.7)    | 1.786\(^a\) | 0.074 |
| Blood potassium                                 | 4.38 (3.87, 4.92) | 4.43 (3.87, 4.92)     | 4.27 (3.75, 4.9)   | 0.565\(^a\) | 0.572 |
| Gender, n(%)                                    | 2.561\(^c\)    |                          |                     | 0.110      |
| Male                                           | 44 (32.12)      | 36 (36)                  | 8 (21.62)          | 29 (78.38) |
| Female                                         | 93 (67.88)      | 64 (64)                  |                     |             |
| Hypertension, n (%)                             | 1.876\(^c\)    |                          |                     | 0.171      |
| No                                             | 65 (47.45)      | 51 (51)                  | 14 (37.84)         | 23 (62.16) |
| Yes                                            | 72 (52.55)      | 49 (49)                  |                     |             |
| Diabetes, n(%)                                  | 0.1\(^c\)       |                          |                     | 0.751      |
| No                                             | 99 (72.26)      | 73 (73)                  | 26 (70.27)         | 11 (29.73) |
| Yes                                            | 38 (27.74)      | 27 (27)                  |                     |             |
| Stroke, n(%)                                    | 4.606\(^c\)    |                          |                     | 0.032      |
| No                                             | 103 (75.18)     | 80 (80)                  | 23 (62.16)         | 14 (37.84) |
| Yes                                            | 34 (24.82)      | 20 (20)                  |                     |             |

(Continued)
Table 1 (Continued).

| Variables                                             | Total (n = 137) | Survival Group (n = 100) | Death Group (n = 37) | Statistic | P   |
|--------------------------------------------------------|-----------------|--------------------------|----------------------|-----------|-----|
| Heart disease, n(%)                                     |                 |                          |                      |           |     |
| No                                                     | 73 (53.28)      | 57 (57)                  | 16 (43.24)           | 2.053c    | 0.152 |
| Yes                                                    | 64 (46.72)      | 43 (43)                  | 21 (56.76)           |           |     |
| History of kidney disease, n (%)                        |                 |                          |                      |           |     |
| No                                                     | 88 (64.23)      | 59 (59)                  | 29 (78.38)           | 4.415c    | 0.036 |
| Yes                                                    | 49 (35.77)      | 41 (41)                  | 8 (21.62)            |           |     |
| Anemia, n(%)                                           |                 |                          |                      |           |     |
| No                                                     | 90 (65.69)      | 64 (64)                  | 26 (70.27)           | 0.471c    | 0.492 |
| Yes                                                    | 47 (34.31)      | 36 (36)                  | 11 (29.73)           |           |     |
| Tumor, n(%)                                            |                 |                          |                      |           |     |
| No                                                     | 119 (86.86)     | 86 (86)                  | 33 (89.19)           |           |     |
| Yes                                                    | 18 (13.14)      | 14 (14)                  | 4 (10.81)            |           |     |
| Blood transfusion, n(%)                                 |                 |                          |                      |           |     |
| No                                                     | 102 (74.45)     | 74 (74)                  | 28 (75.68)           | 0.04c     | 0.842 |
| Yes                                                    | 35 (25.55)      | 26 (26)                  | 9 (24.32)            |           |     |
| Gastrointestinal bleeding, n (%)                        |                 |                          |                      |           |     |
| No                                                     | 112 (81.75)     | 84 (84)                  | 28 (75.68)           | 1.255c    | 0.263 |
| Yes                                                    | 25 (18.25)      | 16 (16)                  | 9 (24.32)            |           |     |
| Intestinal obstruction, n (%)                           |                 |                          |                      |           |     |
| No                                                     | 135 (98.54)     | 99 (99)                  | 36 (97.3)            |           |     |
| Yes                                                    | 2 (1.46)        | 1 (1)                    | 1 (2.7)              |           |     |
| Multiple injuries, n%                                   |                 |                          |                      |           |     |
| No                                                     | 133 (97.08)     | 97 (97)                  | 36 (97.3)            |           |     |
| Yes                                                    | 4 (2.92)        | 3 (3)                    | 1 (2.7)              |           |     |
| Hepatobiliary and pancreatic diseases, n(%)             |                 |                          |                      |           |     |
| No                                                     | 117 (85.4)      | 88 (88)                  | 29 (78.38)           | 2.005c    | 0.157 |
| Yes                                                    | 20 (14.6)       | 12 (12)                  | 8 (21.62)            |           |     |
| Pulmonary infection, n(%)                               |                 |                          |                      |           |     |
| No                                                     | 59 (43.07)      | 47 (47)                  | 12 (32.43)           | 2.338c    | 0.126 |
| Yes                                                    | 78 (56.93)      | 53 (53)                  | 25 (67.57)           |           |     |
| CPR, n (%)                                              |                 |                          |                      |           |     |
| No                                                     | 126 (91.97)     | 97 (97)                  | 29 (78.38)           |           |     |
| Yes                                                    | 11 (8.03)       | 3 (3)                    | 8 (21.62)            |           |     |
| MV, n (%)                                               |                 |                          |                      |           |     |
| No                                                     | 89 (64.96)      | 77 (77)                  | 12 (32.43)           | 23.568c   | < 0.001 |
| Yes                                                    | 48 (35.04)      | 23 (23)                  | 25 (67.57)           |           |     |
| Surgery, n(%)                                           |                 |                          |                      |           |     |
| No                                                     | 116 (84.67)     | 81 (81)                  | 35 (94.59)           | 3.846c    | 0.050 |
| Yes                                                    | 21 (15.33)      | 19 (19)                  | 2 (5.41)             |           |     |
| Hemorrhagic shock, n(%)                                 |                 |                          |                      |           |     |
| No                                                     | 134 (97.81)     | 97 (97)                  | 37 (100)             |           |     |
| Yes                                                    | 3 (2.19)        | 3 (3)                    | 0 (0)                |           |     |

(Continued)
standard in the “Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis” (TRIPOD) statement, the bootstrap method (resampling 1000 times) was used for internal validation of the nomogram model. A $P$-value <0.05 was considered statistically significant.

### Results

#### Comparison of Clinical Data Between Groups

The in-hospital mortality of AKI patients in the ICU was 27.01% (37/137). The median age of subjects was 64 (52.74) years-old, and the sample included 93 (67.88%) males and 44 (32.12%) females. In the 137 subjects, 72 (52.55%) patients had hypertension, 38 (27.74%) had diabetes and 34 (24.82) had suffered a stroke. Differences between the death group and survival group were statistically significant ($P <0.05$), for the following variables: age, systolic blood pressure within 24 h of AKI onset (hereafter, “systolic BP”), diastolic blood pressure within 24 h of AKI onset, mean arterial pressure within 24 h of AKI onset, albumin value, platelet value, white blood cell count, occurrence of a stroke, history of kidney disease, whether CPR was performed during hospitalization (hereafter, “CPR”), whether MV was performed during hospitalization (hereafter, “MV”), whether surgery was performed during hospitalization (hereafter, “surgery”), presence of infectious shock, application of vasoactive drugs.

#### Table 1 (Continued).

| Variables                    | Total (n = 137) | Survival Group (n = 100) | Death Group (n = 37) | Statistic | $P$   |
|------------------------------|----------------|-------------------------|---------------------|-----------|------|
| Septic shock, n(%)          |                |                         |                     |           |      |
| No                           | 100 (72.99)    | 80 (80)                 | 20 (20)             | 9.223$^c$ | 0.002|
| Yes                          | 37 (27.01)     | 20 (20)                 | 17 (45.95)          |           |      |
| Cardiogenic shock, n(%)     |                |                         |                     |           |      |
| No                           | 130 (94.89)    | 96 (96)                 | 34 (91.89)          |           |      |
| Yes                          | 7 (5.11)       | 4 (4)                   | 3 (8.11)            |           |      |
| Sepsis, n(%)                 |                |                         |                     |           |      |
| No                           | 127 (92.7)     | 93 (93)                 | 34 (91.89)          |           |      |
| Yes                          | 10 (7.3)       | 7 (7)                   | 3 (8.11)            |           |      |
| Vasoactive drugs, n(%)      |                |                         |                     |           |      |
| No                           | 104 (75.91)    | 89 (89)                 | 15 (40.54)          | 34.684$^c$| <0.001|
| Yes                          | 33 (24.09)     | 11 (11)                 | 22 (59.46)          |           |      |
| Liver failure, n(%)          |                |                         |                     |           |      |
| No                           | 113 (82.48)    | 85 (85)                 | 28 (75.68)          | 1.625$^c$ | 0.202|
| Yes                          | 24 (17.52)     | 15 (15)                 | 9 (24.32)           |           |      |
| Heart failure, n(%)          |                |                         |                     |           |      |
| No                           | 106 (77.37)    | 78 (78)                 | 28 (75.68)          | 0.083$^c$ | 0.773|
| Yes                          | 31 (22.63)     | 22 (22)                 | 9 (24.32)           |           |      |
| Respiratory failure, n(%)   |                |                         |                     |           |      |
| No                           | 87 (63.5)      | 70 (70)                 | 17 (45.95)          | 6.742$^c$ | 0.009|
| Yes                          | 50 (36.5)      | 30 (30)                 | 20 (54.05)          |           |      |
| Hemodialysis, n(%)          |                |                         |                     |           |      |
| No                           | 106 (77.37)    | 78 (78)                 | 28 (75.68)          | 0.083$^c$ | 0.773|
| Yes                          | 31 (22.63)     | 22 (22)                 | 9 (24.32)           |           |      |
| Start CRRT, n(%)            |                |                         |                     |           |      |
| No                           | 66 (48.18)     | 56 (56)                 | 10 (27.03)          | 9.08$^c$  | 0.003|
| Yes                          | 71 (51.82)     | 44 (44)                 | 27 (72.97)          |           |      |

Notes: $^a$ Mann–Whitney test, $^b$ Independent sample t-test, $^c$ Pearson chi-square test, $^d$ Fisher exact probability method.
drugs (hereafter, “vasoactive drugs”), presence of respiratory failure and whether CRRT was initiated. See Table 1 for details.

Variables Related to In-Hospital Death in ICU Patients with AKI

Given the many variables identified as statistically significant by univariate analysis (Table 1) and the substantially fewer patients in the death group, the “glmnet” package was used for LASSO regression to further explore the 16 identified variables and hone in on those variables characteristic of in-hospital death in AKI patients. When selecting the optimal lambda parameters, 10 times cross validation was used, the lambda value at the time of minimum cross validation error was taken as the optimal value of the model (Figure 1) and the number of variables with a non-zero regression coefficient counted. LASSO regression showed that the lambda value when the cross-validation error was minimized was 0.0263. This corresponded to a model in which nine variables had a non-zero regression coefficient, including age, systolic BP, albumin value, platelet value, a history of kidney disease, CPR, MV, surgery, and vasoactive drugs. See Figure 1A and B and Table 2 for details.

Multivariate Regression Analysis of In-Hospital Mortality Risk of AKI Patients in ICU

The clinical outcome of 137 patients with AKI was used as the dependent variable, and the nine predictor variables identified by the LASSO regression used as the independent variables in a multivariate logistic regression model. The variable selection method used was a stepwise regression based on minimum Aikke Information Criterion (AIC). Multivariate logistic regression analysis based on minimum AIC showed that age, albumin value, CPR, MV, surgery, and vasoactive drugs were independent risk factors for in-hospital death of AKI patients (Figure 2).

Development of the Nomogram Model for Predicting In-Hospital Mortality Risk of ICU Inpatients with AKI

Although only the regression coefficients of age, MV and vasoactive drugs were statistically significant (P <0.05), considering the clinical practicability of minimal AIC screening variables, we included all six variables identified by multivariate regression analysis based on the minimal AIC when constructing the nomogram model. The nomogram model for predicting the in-hospital mortality risk of
ICU hospitalized AKI patients was plotted with the “rms” package (Figure 3). Timing for the collection of predictors in the nomogram model was as follows. Age was collected from the admission assessment sheet when the patient was admitted to the ICU. Albumin value was tested and collected within 24 hours of AKI diagnosis. After AKI was diagnosed, the status of the predictors regarding use of CPR, MV, surgery, or vasoactive drugs was updated at the time of use.

Analysis of Clinical Applicability and Prediction Efficiency of the Nomogram Model

The DCA curve of the nomogram model was plotted using the “rmda” package (Figure 4). According to the DCA curve, when the prediction probability threshold was between 0.01 and 0.75, the nomogram model had the highest level of clinical net benefit and was better than the “all intervention” curve and “no intervention” curve, suggesting that the nomogram model had good clinical applicability. The Harrell’s C-index of the nomogram prediction model for internal data was 0.891 (95% CI: 0.837–0.945). For internal validation, higher values of C-index may simply indicate model overfitting. To prevent overfitting, the nomogram model was verified internally using the bootstrap method. The area under the ROC curve (AUC) was 0.886 (95% CI: 0.823–0.936) after using the bootstrap method for internal validation, indicating that the nomogram model has good discrimination ability. See Figures 5A and B for details. The Hosmer-Lemeshow goodness of fit test

| Variables                        | Coefficient of the LASSO Regression |
|----------------------------------|-------------------------------------|
| Constant                         | -1.319                              |
| Age                              | 0.616                               |
| Vasoactive drugs                 | 0.579                               |
| MV                               | 0.373                               |
| CPR                              | 0.266                               |
| Albumin value                    | -0.200                              |
| Systolic blood pressure within 24 hours after AKI | -0.072    |
| Surgery                          | -0.105                              |
| Platelet value                   | -0.052                              |
| History of kidney disease        | -0.042                              |

**Abbreviations:** LASSO regression, Least absolute shrinkage and selection operator regression; CPR, cardio-pulmonary resuscitation; MV, mechanical ventilation; AKI, acute kidney injury.

| Variables                        | OR(95%CI)         | P value |
|----------------------------------|-------------------|---------|
| Age                              | 1.06 (1.02−1.10)  | 0.004   |
| Albumin value                    | 0.94 (0.86−1.02)  | 0.133   |
| CPR(Reference=No)                | 4.93 (0.95−33.97) | 0.072   |
| MV(Reference=No)                 | 3.23 (1.12−9.38)  | 0.029   |
| Surgery(Reference=No)            | 0.29 (0.03−1.53)  | 0.187   |
| Vasoactive drugs (Reference=No)  | 5.93 (1.94−19.35) | 0.002   |

**Figure 2** The multivariate regression of in-hospital mortality risk of AKI patients in ICU. The x-axis of the second figure in Figure 2 represents the null line, ie, OR = 1, indicating no statistical association between the studied factor and the outcome. When the error line for the studied factor intersects this line, it suggests that P >0.05 and the 95% CI for OR includes 1.

**Abbreviations:** CPR, cardio-pulmonary resuscitation; MV, mechanical ventilation.
showed that the prediction deviation between the risk prediction value of the nomogram and the actual frequency of death in ICU patients with AKI was not statistically significant ($\chi^2 = 5.660, P = 0.685$). The calibration curve showed that the deviation correction curve of the nomogram model was consistent with the ideal curve, indicating that the nomogram model has good calibration and prediction consistency. See Figure 6A and B for details.

**Discussion**

In the last 3 years, a number of reports on the prognosis of patients with AKI in the ICU in China have suggested that in-hospital mortality of AKI patients in the ICU can reach 13.58% to 60.92%\textsuperscript{16–18}. Our data were consistent with this, with an in-hospital mortality rate for AKI patients of 27.01%. The in-hospital mortality of AKI patients in the ICU in China appears to be relatively high. Identifying risk factors for in-hospital mortality of AKI patients in the ICU is thus an important practical step to allow medical staff to identify patients with high risk of in-hospital mortality, implement early warning and prevention strategies, improve the prognosis of patients, and reduce the risk of death.

The results of this study are similar to previous studies\textsuperscript{19–21} that found age, hypoproteinemia, and whether surgery was performed during hospitalization are predictors of in-hospital death in AKI patients. In addition, this study found that use of MV, CPR and vasoactive drugs during hospitalization were closely related to the risk of in-hospital death in ICU patients with AKI. One reason that MV is closely related to mortality risk may be that it is a commonly used life support method in the ICU, through which the life of critically ill patients can be extended.\textsuperscript{22} However, in recent years, studies have shown that patients under MV for a long time become dependent on the ventilator, leading to difficulties in ventilator withdrawal. Of patients with long-term MV, 25–40% have difficulty with ventilator withdrawal, and 30–40% of patients may die from ventilator withdrawal.\textsuperscript{23–26} Vasoactive drugs are commonly used in the treatment of critically ill patients. These drugs need accurate treatment targets, close monitoring for changes in vital signs, titration to the minimum

![Nomogram model for predicting in-hospital mortality risk in ICU patients with AKI. A vertical line upwards from the specific value of each of the six predictors on the horizontal axis to the horizontal axis of "Points" gives the score. The scores of the six indicators are then summed to obtain the total score. From the position of the total score on the horizontal axis of "Total Points", a vertical line is drawn downward to obtain the probability value on “Risk of poor prognosis in ICU patients with AKI.” This is the probability of death for AKI patient in ICU.](https://doi.org/10.2147/RMHP.S321399)
effective dose and the drug must be stopped as soon as possible, or the hospitalization time of patients will be prolonged, and the risk of adverse prognostic events such as myasthenia, hypotension, shock and death is increased. This is consistent with our finding that the proportion of vasoactive drugs used in the death group was significantly higher than that in the survival group for this study. With the continuous improvement and popularization of CPR, the resuscitation rate from cardiac arrest has been correspondingly improved. However, few patients survive and leave hospital after successful resuscitation of cardiac arrest, and the mortality rate of patients after successful CPR is still high, which was consistent with the results of this study.

A nomogram is a type of visual graph used to predict the probability of a clinical event that intuitively displays the statistical model and accurately quantifies risk. The nomogram can be used for predicting the risk of AKI related to cardiac surgery, in septic patients after admission, and after nephrotic surgery. This study constructed the first nomogram model to predict the risk of in-hospital death in patients with AKI in China based on the risk factors of in-hospital death in the ICU for patients with AKI. Harrell’s C-index, AUC of the ROC curve after internal validation, the Hosmer-Lemeshow goodness of fit test and the DCA curve were used to evaluate the predictive efficiency and clinical applicability of the nomogram model. Harrell’s C-index indicated the nomogram model has good discrimination ability. The Hosmer-Lemeshow goodness of fit test showed the prediction value of the

---

**Figure 4** Clinical decision analysis curve of nomogram model. The x-axis, the threshold probability, indicates the predicted probability of the occurrence of an event in the sample, based on the model. This is defined as positive for intervention and treatment at this time. The corresponding y-axis indicates the net benefit obtained. For the DCA curve of the nomogram model (red-brown solid line), the horizontal dashed line (No intervention, Orange line) indicates the net benefit of not taking the intervention at any threshold probability, and the diagonal dashed line (All interventions, blue line) indicates the net benefit of always taking the intervention.

---

**Figure 5** ROC curve of nomogram model. (A) ROC curve before internal validation. (B) ROC curve after internal validation. In both plots the y-axis is 1 minus the sensitivity of the nomogram and the x-axis is the specificity of the nomogram. 

**Abbreviations:** ROC, receiver operating characteristic; AUC, area under curve.
nomogram matches the actual frequency of the death in patients with AKI in the ICU. The calibration curve showed that the nomogram model has good calibration and prediction consistency. The DCA curve suggested that the nomogram model had good clinical applicability. Thus, the nomogram model appears to have good prediction efficiency and clinical applicability. It can be used to predict the risk of in-hospital death of ICU hospitalized AKI patients, assist medical staff to screen out patients with high risk of in-hospital death, and carry out targeted risk intervention.

**Limitations**

The first limitation of this study is that the data are from a single-center retrospective study that includes complete clinical data for only 137 patients with possible retrospective bias. As such, the data are insufficient to achieve the goal of the study, which would require thousands of patients at multiple centers. Carrying out multicenter, large sample size data collection to analyze the clinical application of the nomogram will be the focus of our next study. Second, this study only carried out internal validation. Validation of the nomogram using external populations to assess prediction efficiency will also be the focus of the next study. Third, the nomogram developed in this study only includes six variables (age, albumin level, CPR, MV, surgical treatment and vasoactive drugs) and this may limit further improvement in the prediction efficiency of the nomogram. It is thus also necessary to carry out prospective research on incorporating more risk factors and improving the prediction efficiency of the nomogram. Fourth, as AKI is a time-varying event that can develop and resolve within the course of an ICU stay, it can be better captured in a time-to-event model rather than a logistic regression model. At the same time, excess fluid balance in AKI may be harmful and some patients may react to fluid challenges. Differentiating volume-responsive (VR) and volume-unresponsive (VU) AKI, and analyzing the impact of fluid responsiveness on the final outcome of AKI patients may also be important for predicting the risk of poor prognosis in ICU patients with AKI. Therefore, future prospective studies should consider the prediction efficiency of fluid responsiveness for AKI patients.

**Conclusion**

In summary, ICU inpatients with AKI have high in-hospital mortality that is affected by age, albumin level within 24 hours of AKI, whether MV was used, whether vasoactive drugs were used, whether surgery was performed, and whether CPR was performed. The nomogram risk prediction model based on these six risk factors appears to have good prediction efficiency and clinical applicability to help medical staff identify AKI patients with high mortality risk as early as possible and to address relevant risk factors to improve the adverse prognosis of AKI patients.
Ethics Approval
The protocol of this study was approved by the medical ethics committee of The First Affiliated Hospital of the University of Science and Technology of China (2021-RE-037) and followed the guidelines of the “Declaration of Helsinki.” As this study was a retrospective study and the data was analyzed anonymously, informed consent of the subjects was not required.

Funding
This study was not supported by any funding.

Disclosure
The authors declare that the manuscript content was composed in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References
1. Zhang Q, Guo S, Liang X, et al. Risk prediction and key influencing factors of acute kidney injury in hospitalized patients. Chin J Biomed Eng. 2019;38(06):702–710.
2. Lin L, Chen X, Chen J. Analysis of death related factors of hospitalized super elderly patients with acute kidney injury. Chin J Mod Med. 2020;30(1):115–119.
3. Ruiz-Criado J, Ramos-Barron MA, Fernandez-Fresneda G, et al. Long-term mortality among hospitalized non-ICU patients with acute kidney injury referred to nephrology. Nephron. 2015;131(1):23–33.
4. Pickering JW, Blunt I, Than MP. Acute kidney injury and mortality: a meta-analysis. Nephrology. 2018;23(3):237–246. doi:10.1111/npn.12984
5. Yang L, Xing G, Wang L, et al. Acute kidney injury in China: a cross-sectional survey. Lancet. 2015;386(10002):1465–1471. doi:10.1016/S0140-6736(15)00344-X
6. Feng Z. Prospective Epidemiological Study on Acute Kidney Injury of Hospitalized Patients in Multi-Center in China [D]. PLA General Hospital (Beijing 301 Hospital) & Military Medical College of Continuing Education; 2015.
7. Gong F, Yang X. Pay attention to the recovery of kidney - further discussion on the prevention and treatment strategy of acute kidney injury. J Med Postgrad. 2020;33(01):1–6.
8. Meersch M, Schmidt C, Hoffmeier A, et al. Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. Intensive Care Med. 2017;43(11):1551–1561. doi:10.1007/s00134-016-4670-3
9. Harrell Jr, Frank E. rms: Regression modeling strategies. R package version 5, no. 2, 2016.
10. Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinform. 2011;12:77. doi:10.1186/1471-2105-12-77
11. Brown M. random: Risk Model Decision Analysis[J]. R package version 1.6, 2018.
12. N A Z, Ramspeck CL, Dekker FW, et al. TRIPOD statement: a preliminary pre-post analysis of reporting and methods of prediction models. BMJ Open. 2020;10(9):e031537.
13. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1–22. doi:10.18637/jss.v033.i01
33. Zhang Z, Reinikainen J, Adeleke KA, Pieterse ME, Groothuis-Oudshoorn CGM. Time-varying covariates and coefficients in cox regression models. *Ann Transl Med*. 2018;6(7):121. doi:10.21037/atm.2018.02.12

34. Zhang Z, Ho KM, Hong Y. Machine learning for the prediction of volume responsiveness in patients with oliguric acute kidney injury in critical care. *Crit Care*. 2019;23(1):112. doi:10.1186/s13054-019-2411-z